Browse by Phase
Phase 2 Clinical Trials
Phase 2 trials study whether a drug works in people with a specific disease or condition. These studies enroll 100–300 participants and also continue to evaluate safety.
Total Trials
1,068
Recruiting Now
1,068
Top Conditions in Phase 2
Frequently Asked Questions — Phase 2 Trials
What does a Phase 2 clinical trial evaluate?
Phase 2 trials assess whether a drug or treatment works in people with a specific disease or condition. Enrolling 100–300 participants, these studies collect preliminary efficacy data while continuing to monitor safety and identify the optimal dosing regimen. A successful Phase 2 outcome is required to advance to large-scale Phase 3 testing.
How long do Phase 2 trials typically take?
Phase 2 clinical trials typically run for 1–4 years, depending on the condition, endpoint complexity, and enrollment rate. Rare disease trials or those with long-term outcome measures may run longer. Many sponsors run Phase 2 studies at multiple sites simultaneously to accelerate recruitment.
Who can participate in a Phase 2 clinical trial?
Eligibility for Phase 2 trials is defined by specific inclusion and exclusion criteria. Participants are typically patients diagnosed with the condition under study and may or may not have received prior treatment. Age, disease stage, comorbidities, and laboratory values are common eligibility factors. Review each trial's criteria on ClinicalTrials.gov for specific requirements.
Active Phase 2 Studies
NCT06675357 Phase 2
Recruiting
Using FAPI PET/MRI to Evaluate Prostate Cancer
Condition
Prostate Cancer Metastatic Disease
Enrollment
30 pts
Location
United States
Sponsor
University of Wisconsin, Madis
NCT07166211 Phase 2
Recruiting
Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
Condition
Chronic Spontaneous Urticaria (CSU)
Enrollment
48 pts
Location
China
Sponsor
Keymed Biosciences Co.Ltd
NCT07503756 Phase 2
Recruiting
JS212 Combination Therapies in Metastatic Colorectal Cancer
Condition
Metastatic Colorectal Cancer
Enrollment
80 pts
Location
China
Sponsor
Shanghai Junshi Bioscience Co.
NCT04696029 Phase 2
Recruiting
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medul...
Condition
Medulloblastoma
Enrollment
118 pts
Location
United States, Canada
Sponsor
Giselle Sholler
NCT07530172 Phase 2
Recruiting
Radioembolization Versus External Radiation Therapy
Condition
Heptocellular Cancer
Enrollment
146 pts
Location
United States
Sponsor
Henry Ford Health System
NCT06031428 Phase 2
Recruiting
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly ...
Condition
Diabetes Mellitus, Type 2
Enrollment
100 pts
Location
United States
Sponsor
Medical College of Wisconsin
NCT05483400 Phase 2
Recruiting
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumor...
Condition
Head and Neck Neoplasms
Enrollment
97 pts
Location
Netherlands
Sponsor
University Medical Center Gron
NCT06799195 Phase 2
Recruiting
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Condition
Hematological Malignancies
Enrollment
126 pts
Location
United States
Sponsor
University of Nebraska
NCT06563505 Phase 2
Recruiting
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Ref...
Condition
Lymphoma
Enrollment
36 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT07239466 Phase 2
Recruiting
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-...
Condition
Rectal Cancer
Enrollment
25 pts
Location
China
Sponsor
Tao Zhang
NCT06985472 Phase 2
Recruiting
Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL
Condition
Initial MZL
Enrollment
33 pts
Location
China
Sponsor
Li Zhiming
NCT06686472 Phase 2
Recruiting
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Condition
Allergic Conjunctivitis
Enrollment
66 pts
Location
United States
Sponsor
Telios Pharma, Inc.
NCT07321301 Phase 2
Recruiting
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refract...
Condition
B-cell Lymphoma Refractory
Enrollment
10 pts
Location
China
Sponsor
Daihong Liu
NCT05027945 Phase 2
Recruiting
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects W...
Condition
Immunodeficiency
Enrollment
54 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT07325539 Phase 2
Recruiting
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Condition
Nasopharyngeal Cancinoma (NPC)
Enrollment
55 pts
Location
China
Sponsor
Sun Yat-sen University
NCT06749730 Phase 2
Recruiting
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line...
Condition
Unresectable Biliary Tract Carcinoma
Enrollment
63 pts
Location
China
Sponsor
Henan Cancer Hospital
NCT07688356 Phase 2
Recruiting
Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors
Condition
Primary Brain Tumor
Enrollment
30 pts
Location
South Korea
Sponsor
Samsung Medical Center
NCT07121322 Phase 2
Recruiting
Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.
Condition
Refractory Germ Cell Tumors
Enrollment
33 pts
Location
Slovakia
Sponsor
National Cancer Institute, Slo
NCT06686537 Phase 2
Recruiting
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
Condition
Infertility, Female
Enrollment
20 pts
Location
United States
Sponsor
University of Colorado, Denver
NCT06282445 Phase 2
Recruiting
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and ...
Condition
Colorectal Cancer Metastatic
Enrollment
36 pts
Location
China
Sponsor
The Fourth Affiliated Hospital
NCT04299581 Phase 2
Recruiting
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahep...
Condition
Intrahepatic Cholangiocarcinoma
Enrollment
25 pts
Location
China
Sponsor
Fudan University
NCT06136546 Phase 2
Recruiting
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Vi...
Condition
Depressive Disorder, Major
Enrollment
100 pts
Location
United States
Sponsor
Massachusetts General Hospital
NCT06123715 Phase 2
Recruiting
Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty
Condition
Chronic Pain
Enrollment
400 pts
Location
Canada
Sponsor
University Health Network, Tor
NCT06514313 Phase 2
Recruiting
Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tis...
Condition
Soft Tissue Sarcoma
Enrollment
110 pts
Location
China
Sponsor
Yizhuo Zhang
NCT06693323 Phase 2
Recruiting
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx fo...
Condition
HNSCC
Enrollment
34 pts
Location
United States
Sponsor
University of California, Irvi
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology